ARCHIVES

Palbocicilib Doubles PFS In Phase II Trial to 20.2 Months

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: FDA’s Burlington Moves to Wyeth-Ayerst; NAS Award to Beckman; Genetics Online

February 5, 1999

In Brief: WHI Revises Protocol After Study Finds High Rate Of Endometrial Hyperplasia

January 27, 1995

Cancer Advocates Use Benefit Analysis To Press For Funds

May 11, 1990

NCI To Study Whether It Gets The Most From Advisors.

March 8, 2002

HPV DNA Testing Reduced Cervical Cancer Precursors

September 24, 2010

TA To Release Report On Burton Therapy Requested By Congress

February 9, 1990